Bemcentinib
![](https://mb.cision.com/Public/15728/2491305/bcfcb3bee4a9d605_800x800ar.jpg)
Photographer: Nils Olav Mevatne
Photographer: Nils Olav Mevatne
BerGenBio is a clinical-stage biopharmaceutical company focused on developing transformative drugs targeting AXL as a potential cornerstone of therapy for aggressive diseases, including cancer and severe respiratory infections. The Company is focused on its proprietary lead candidate, bemcentinib, a potentially first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC and severe respiratory infections.